Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2025)

Xilio Therapeutics' EBITDA Margin history spans 2 years, with the latest figure at 85.42% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 53411.0% year-over-year to 85.42%; the TTM value through Sep 2025 reached 183.9%, changed N/A, while the annual FY2024 figure was 918.05%, N/A changed from the prior year.
  • EBITDA Margin for Q3 2025 was 85.42% at Xilio Therapeutics, up from 195.99% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 85.42% in Q3 2025 and bottomed at 759.45% in Q4 2024.